Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Oct;83(8):980–985. doi: 10.1054/bjoc.2000.1418

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study

M J Allen 1, M Vaughan 1, A Webb 1, S Johnston 1, P Savage 1, T Eisen 1, S Bate 1, J Moore 1, R Ahern 1, M E Gore 1
PMCID: PMC2363554  PMID: 10993642

Abstract

Our purpose was to assess the activity of alpha-interferon (IFN-α), interleukin-2 (IL-2) and 5 fluorouracil (5FU) administered by protracted venous infusion (PVI) as opposed to bolus injection. 55 patients with advanced renal cell cancer were treated as follows: IL-2 and IFN-α according to the schedule originally described by Atzpodien, with PVI 5FU 200 mg m–2 day–1 during weeks 5–9. 42 patients (76%) were of moderate or poor prognosis as defined by previous studies. The response rate by intention to treat was 31% (17 of 55, three complete response, 14 partial response; 95% CI = 19–45%) and in evaluable patients (completed one cycle, n = 42), it was 40% (95% CI = 26–57%). In addition, 24% (13 of 55) patients achieved disease stabilization. The overall median survival was 11 months with a 1-year survival of 45%. The median survival for evaluable patients was 18 months with 1- and 2-year survivals of 60% and 40% respectively. The median survival of responding patients was 31 months and the three patients achieving complete response remain progression-free at 14+, 18+ and 23+ months. Evaluable patients with poor prognostic features achieved a response rate of 54% and median survival of 18 months. Toxicity was significant yet manageable with 12 patients unable to complete one cycle due to side-effects and 36% experiencing grade 3–4 toxicities. The three on-treatment deaths were considered unlikely to be due to toxicity. The schedule of IFN-α, IL-2 and PVI 5FU has significant activity in advanced renal cell cancer with manageable toxicity. It is of particular interest that this regimen appears to have high activity in fit patients with poor prognostic features. © 2000 Cancer Research Campaign

Keywords: renal cell cancer, interleukin-2, interferon, 5-fluorouracil, biochemotherapy

Full Text

The Full Text of this article is available as a PDF (69.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atzpodien J., Kirchner H., Hänninen E. L., Deckert M., Fenner M., Poliwoda H. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer. 1993;29A Suppl 5:S6–S8. doi: 10.1016/0959-8049(93)90617-o. [DOI] [PubMed] [Google Scholar]
  2. Bukowski R. M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997 Oct 1;80(7):1198–1220. doi: 10.1002/(sici)1097-0142(19971001)80:7<1198::aid-cncr3>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  3. Ellerhorst J. A., Sella A., Amato R. J., Tu S. M., Millikan R. E., Finn L. D., Banks M., Logothetis C. J. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer. 1997 Dec 1;80(11):2128–2132. [PubMed] [Google Scholar]
  4. Elson P. J., Witte R. S., Trump D. L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 1988 Dec 15;48(24 Pt 1):7310–7313. [PubMed] [Google Scholar]
  5. Fossa S., Jones M., Johnson P., Joffe J., Holdener E., Elson P., Ritchie A., Selby P. Interferon-alpha and survival in renal cell cancer. Br J Urol. 1995 Sep;76(3):286–290. doi: 10.1111/j.1464-410x.1995.tb07702.x. [DOI] [PubMed] [Google Scholar]
  6. Fyfe G., Fisher R. I., Rosenberg S. A., Sznol M., Parkinson D. R., Louie A. C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995 Mar;13(3):688–696. doi: 10.1200/JCO.1995.13.3.688. [DOI] [PubMed] [Google Scholar]
  7. Hofmockel G., Langer W., Theiss M., Gruss A., Frohmüller H. G. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol. 1996 Jul;156(1):18–21. [PubMed] [Google Scholar]
  8. Joffe J. K., Banks R. E., Forbes M. A., Hallam S., Jenkins A., Patel P. M., Hall G. D., Velikova G., Adams J., Crossley A. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol. 1996 May;77(5):638–649. doi: 10.1046/j.1464-410x.1996.09573.x. [DOI] [PubMed] [Google Scholar]
  9. Jones M., Philip T., Palmer P., von der Maase H., Vinke J., Elson P., Franks C. R., Selby P. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother. 1993 Winter;8(4):275–288. doi: 10.1089/cbr.1993.8.275. [DOI] [PubMed] [Google Scholar]
  10. Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989 Apr;7(4):425–432. doi: 10.1200/JCO.1989.7.4.425. [DOI] [PubMed] [Google Scholar]
  11. Minasian L. M., Motzer R. J., Gluck L., Mazumdar M., Vlamis V., Krown S. E. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. 1993 Jul;11(7):1368–1375. doi: 10.1200/JCO.1993.11.7.1368. [DOI] [PubMed] [Google Scholar]
  12. Muss H. B. The use of interferon in renal cell carcinoma. Eur J Cancer. 1991;27 (Suppl 4):S84–S87. doi: 10.1016/0277-5379(91)90585-2. [DOI] [PubMed] [Google Scholar]
  13. Negrier S., Escudier B., Lasset C., Douillard J. Y., Savary J., Chevreau C., Ravaud A., Mercatello A., Peny J., Mousseau M. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med. 1998 Apr 30;338(18):1272–1278. doi: 10.1056/NEJM199804303381805. [DOI] [PubMed] [Google Scholar]
  14. Palmer P. A., Vinke J., Philip T., Negrier S., Atzpodien J., Kirchner H., Oskam R., Franks C. R. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol. 1992 Jun;3(6):475–480. doi: 10.1093/oxfordjournals.annonc.a058239. [DOI] [PubMed] [Google Scholar]
  15. Rabinovitch R. A., Zelefsky M. J., Gaynor J. J., Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol. 1994 Jan;12(1):206–212. doi: 10.1200/JCO.1994.12.1.206. [DOI] [PubMed] [Google Scholar]
  16. Ravaud A., Audhuy B., Gomez F., Escudier B., Lesimple T., Chevreau C., Douillard J. Y., Caty A., Geoffrois L., Ferrero J. M. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie. J Clin Oncol. 1998 Aug;16(8):2728–2732. doi: 10.1200/JCO.1998.16.8.2728. [DOI] [PubMed] [Google Scholar]
  17. Rosenberg S. A., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994 Mar 23;271(12):907–913. [PubMed] [Google Scholar]
  18. Savage P., Costelna D., Moore J., Gore M. E. A phase II study of continuous infusional 5-fluorouracil (5-FU) and subcutaneous interleukin-2 (IL-2) in metastatic renal cancer. Eur J Cancer. 1997 Jun;33(7):1149–1151. doi: 10.1016/s0959-8049(96)00515-1. [DOI] [PubMed] [Google Scholar]
  19. Selli C., Hinshaw W. M., Woodard B. H., Paulson D. F. Stratification of risk factors in renal cell carcinoma. Cancer. 1983 Sep 1;52(5):899–903. doi: 10.1002/1097-0142(19830901)52:5<899::aid-cncr2820520526>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  20. Smith I. E., Walsh G., Jones A., Prendiville J., Johnston S., Gusterson B., Ramage F., Robertshaw H., Sacks N., Ebbs S. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 1995 Feb;13(2):424–429. doi: 10.1200/JCO.1995.13.2.424. [DOI] [PubMed] [Google Scholar]
  21. Tourani J. M., Pfister C., Berdah J. F., Benhammouda A., Salze P., Monnier A., Paule B., Guillet P., Chretien Y., Brewer Y. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol. 1998 Jul;16(7):2505–2513. doi: 10.1200/JCO.1998.16.7.2505. [DOI] [PubMed] [Google Scholar]
  22. Webb A., Cunningham D., Scarffe J. H., Harper P., Norman A., Joffe J. K., Hughes M., Mansi J., Findlay M., Hill A. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261–267. doi: 10.1200/JCO.1997.15.1.261. [DOI] [PubMed] [Google Scholar]
  23. Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol. 1995 Feb;22(1):42–60. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES